Menu Search
Equities

Clearside Biomedical Inc

CLMG:DEU

Clearside Biomedical Inc

Actions
  • Price (EUR)1.05
  • Today's Change0.02 / 1.94%
  • Shares traded0.00
  • 1 Year change+17.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Clearside Biomedical Inc grew revenues 519.89% from 1.33m to 8.23m while net income improved from a loss of 32.95m to a smaller loss of 32.49m.
Gross margin95.06%
Net profit margin-444.66%
Operating margin-322.06%
Return on assets-91.51%
Return on equity--
Return on investment-107.97%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Clearside Biomedical Inc fell by 19.50m. Cash Flow from Financing totalled 414.00k or 5.03% of revenues. In addition the company used 18.14m for operations while cash used for investing totalled 1.78m.
Cash flow per share-0.4959
Price/Cash flow per share--
Book value per share-0.3785
Tangible book value per share-0.3785
More ▼

Balance sheet in USDView more

Clearside Biomedical Inc uses little or no debt in its capital structure.
Current ratio5.07
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.